These findings suggest that targeting NEK2 may enhance the treatment efficacy, whereas the precise regulatory mechanism of NEK2 for oncogenesis in ESCC remains to be clarified. The gene discussed is NEK2; the disease is esophageal squamous cell carcinoma.